Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMperator: Adjuvant Atezolizumab +/- Tiragolumab in Solid Tumors
NCT06331598Phase 2
Key facts
- Status
- Withdrawn
- Start
- Nov 2024
- Primary completion
- Oct 2028
- Countries
- 1
- Sponsor
- Roche
- Modality
- Immune Checkpoint Inhibitors
- Drugs
- tiragolumab
- Conditions
- solid tumor
01
Overview
Phase 2, randomised, open-label trial of tiragolumab in solid tumor (2 arms), sponsored by Roche. Primary endpoint: Disease Free Survival Rate at 24 months. Planned start Nov 2024; status: withdrawn.
02
Design
2 arms- Study design
- RandomizedOpen-label
Atezolizumab
Atezolizumab Q4W for 12 cycles
Atezolizumab + Tiragolumab
Atezolizumab + Tiragolumab Q4W for 12 cycles
03
Who it enrols
Patients with resectable solid tumors (TMB >= 13 mut/MB or MSI-H) at intermediate-high risk of recurrence who are disease-free after standard radical treatment.
04
Endpoints
Primary
Disease Free Survival Rate
Secondary
Disease Free Survival Rate
Overall Survival
Percentage of Participants With Adverse Events
Beyond the preview
Go deeper on NCT06331598.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06331598.